CSPC Pharmaceutical Group (HKG:1093) expects a 16% year-over-year decrease in profit attributable to owners for the nine months ended Sept. 30 from 4.49 billion yuan a year earlier, according to a Thursday filing with the Hong Kong bourse.
The company attributed this to lower revenue, which in turn was due to the implementation of volume-based procurement by hospitals, impacting sales in key therapeutic areas such as oncology, cardiovascular, and nervous systems.
The company plans to publish its quarterly results on or about Nov. 15.
The pharmaceutical company's shares were down over 8% in the recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments